
Benitec Biopharma fell 38.9% from $13.53 to $8.27, behind the S&P 500's +10.6%. Its worst day was Dec 17 (−13.1%), and its low came Oct 16 at $8.11.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Benitec Biopharma shares fell 13.1%, while the S&P 500 fell 1.1%.
−13.1%, the year's worst day · S&P 500 −1.1%
EPS of $-0.26 missed the $-0.23 estimate on $0.00 revenue.
−2.7% · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
Benitec Biopharma shares rose 10.7%, while the S&P 500 rose 0.9%.
+10.7%, the year's best day · S&P 500 +0.9%
Benitec Biopharma closed at its highest level of the year, 4.1% above where the year started.
+4.6% · S&P 500 +1.2%
EPS of $-0.24 beat the $-0.27 estimate on $0.00 revenue.
+1.7% · S&P 500 +0.8%
EPS of $-0.26 beat the $-0.26 estimate on $0.00 revenue.
−8.5% · S&P 500 −0.5%
Benitec Biopharma shares fell 10.2%, while the S&P 500 fell 0.7%.
−10.2% · S&P 500 −0.7%
Benitec Biopharma closed at its lowest level of the year, 40.1% below where the year started.
−4.1% · S&P 500 −1.1%
Benitec Biopharma shares rose 10.5%, while the S&P 500 rose 1.7%.
+10.5% · S&P 500 +1.7%
EPS of $-0.26 beat the $-0.29 estimate on $0.00 revenue.
−0.6% · S&P 500 −0.4%
Where it ended: a close of $8.27 on Nov 18, 2026. Up next: Q2 2027 earnings on Feb 11, 2027 (EPS est. $-0.30).
Nothing in the past 12 months.
All BNTC dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BNTC and SPY from Benzinga historical bars. Not investment advice.